We are using cookies This website uses cookies in order to offer you the most relevant information. By browsing this website, you accept these cookies.
We consider no immunization versus massimmunization reaching 30% of the population.
2
Its rivals such as Sanofi-Aventis, Novartis and AstraZeneca are also poised to benefit from governments' massimmunization campaigns.
3
In response to the pandemic H1N1 influenza 2009 outbreak, many jurisdictions undertook massimmunization programs that were among the largest in recent history.